Buy Rating for Basilea Pharmaceutica Driven by Cresemba’s Global Success and Zevtera’s U.S. Rollout

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Basilea Pharmaceutica (BSLN – Research Report), retaining the price target of CHF100.00.

Ram Selvaraju has given his Buy rating due to a combination of factors, including the strong performance of Basilea Pharmaceutica’s antifungal product, Cresemba. The sales of Cresemba have surpassed a pre-defined threshold in the Asia Pacific region and China, resulting in a milestone payment from Pfizer. Additionally, Cresemba’s sales in Japan also triggered a separate milestone payment from Asahi Kasei Pharma. The product’s global sales have shown significant growth, establishing it as a leading antifungal agent worldwide.
Another factor contributing to the Buy rating is the ongoing U.S. rollout of Zevtera, Basilea’s proprietary antibiotic, which has been approved by the FDA for specific indications. The agreement with Innoviva Specialty Therapeutics is expected to generate substantial royalty-based revenue for Basilea starting in 2026. Furthermore, the valuation of Basilea is supported by a discounted cash flow analysis, projecting a significant enterprise value based on future revenue from its key products. Despite potential risks, such as market penetration challenges and clinical-stage setbacks, the overall outlook for Basilea remains positive.